Nanohale AG (FYB) | Finanzwire

Basculer en Français

8299	Companies
114942	Keywords
55348	Articles
62469	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 10/16/2024 at 06:55, 1 month 5 days ago

Formycon's Breakthrough in Biosimilar Development

Clinical Trials Formycon AG Biosimilar FYB206 Analytical Similarity Keytruda®
PRESS RELEASE

published on 10/16/2024 at 06:50, 1 month 5 days ago

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
Formycon publishes study results in peer-reviewed journal analyzing biosimilar candidate FYB206 and Keytruda, showing high similarity in structure and function. Results support ongoing clinical trials

Clinical Trials Biosimilar Formycon FYB206 Keytruda
BRIEF

published on 10/01/2024 at 17:11, 1 month 19 days ago

Formycon AG's FYB202 Biosimilar Approved for EU and US Markets

FDA Approval Formycon AG Market Entry Biosimilar Investment Analysis
PRESS RELEASE

published on 10/01/2024 at 17:06, 1 month 19 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects

Investment Recommendation Formycon AG First Berlin Equity Research GmbH FYB202 Approval Biosimilar Market
BRIEF

published on 09/30/2024 at 07:35, 1 month 21 days ago

Formycon and Fresenius Kabi Receive FDA Approval for Biosimilar Otulfi

FDA Approval Biosimilar Formycon Fresenius Kabi Otulfi
PRESS RELEASE

published on 09/30/2024 at 07:30, 1 month 21 days ago

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence

FDA Approval Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 09/27/2024 at 22:01, 1 month 23 days ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®
PRESS RELEASE

published on 09/27/2024 at 21:56, 1 month 23 days ago

EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA grants approval for Stelara Biosimilar FYB202/Otulfi (ustekinumab-aauz) by Formycon AG. Approval based on comprehensive data evaluation. Contact: Sabrina Mueller, Formycon AG

FDA Approval Formycon AG FYB202 Stelara Biosimilar Sabrina Mueller
BRIEF

published on 09/27/2024 at 09:05, 1 month 24 days ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 month 24 days ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval

Accesswire

Published on 11/21/2024 at 14:15, 11 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 26 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 26 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 26 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 26 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 10 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 11 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 26 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 11 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 51 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 28 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 6 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 41 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 41 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE